Plasma SARS-CoV-2 RNA Levels in Critically Ill COVID-19 Patients

Retrospective, observationnal study. Evaluation of the association between plasmatic SARS-CoV-2 RNA and day 60 mortality in ICU adult COVID-19 patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Pneumonia ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Groupe Hospitalier Sud Ile de France, Hôpital de Melun-Sénart

Melun, 77000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age above 18 years
in ICU hospitalization
COVID-19 related pneumonia confirmed by PCR

Exclusion criteria

plasmatic SARS-COV-2 RNA quantification not available
patient's refusal to participate

Treatment and study plan

plasmatic SARS-CoV-2 RNA quantification

Diagnostic Test

plasmatic SARS-CoV-2 RNA was quantified by droplet digital PCR

Primary outcomes

Day 60 mortality

Time frame: 60 days

Association between plasmatic SARS-CoV-2 RNA level and mortality

Sponsors and collaborators

Lead sponsor

Hopital of Melun

Other

Registry information

Official study title

Plasma SARS-CoV-2 RNA Levels in Critically Ill COVID-19 Patients (pRNA-COVID-ICU)

Acronym: pRNA-COVID-ICU

Important dates

Study start: 2021
Primary completion: 2021
Study completion: 2022
First posted: Nov 10, 2021
Registry last updated: Apr 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed